Clinical Trial

Optimizing Subcutaneous FEntanyl titRation: RApid Achievement of Adequate Exposure When Treating Cancer-Related paIn.

Study acronym: FERRARI
Unknown Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated July 12, 2024 (before its estimated November 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
The primary objective is to evaluate the effect of loading boluses when dose incresaing treatment with SC fentanyl in patients with cancer. The primary endpoint of this study is to prove the non-inferiority of fentanyl plasma concentrations 12 hours after dose augmentation compared to 48 hours after dose augmentation within each patient. Patients will be treated with additional loading boluses and plasma-PK samples will be obtained.
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Unknown 2026-08-02
Trial Details
NCT Number NCT06498037
Lead Sponsor Erasmus Medical Center
Conditions Cancer Pain
Enrollment 45 participants
Start Date 2024-02-23
Primary Completion 2025-11-01 (estimated)
Study Completion 2025-12-02 (estimated)
Updated on ClinicalTrials.gov 2024-07-12